SeraCare Life Sciences Unveils New Research Panels for Hepatitis C, Chagas and Dengue - WDRB 41 Louisville News

SeraCare Life Sciences Unveils New Research Panels for Hepatitis C, Chagas and Dengue

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE SeraCare Life Sciences, Inc.

MILFORD, Mass., June 25, 2014 /PRNewswire/ -- SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability, and repeatability across the IVD lifecycle, today announced four new research panels that deliver hard-to-find material for Hepatitis C (HCV), Chagas and Dengue.

SeraCare Worldwide HCV Performance Panel

"Our customers rely on SeraCare to provide the disease materials they need to troubleshoot, challenge, and validate their assays," said Kim Anderson, product manager at SeraCare Life Sciences. "SeraCare's strong global sourcing network enables us to deliver the precise materials our customers require. Our new Worldwide HCV panel is particularly exciting as it delivers a substantial breadth of genotypes with multiple donor samples."

Hepatitis C (HCV) Performance Panel
SeraCare's new Worldwide Hepatitis C (HCV) AccuSet™ Performance Panel is a 20-member panel of undiluted, naturally occurring plasma samples. Panel members represent bleeds from multiple individuals positive for HCV from varying countries of origin. This panel of human plasma samples demonstrates a diverse collection of HCV genotypes 1, 2, 3, 4, 5, and 6 with varying subtypes. Test results from commercially-available HCV genotype, RNA, and antibody assays are included for characterization of the panel members.

Chagas Seroconversion and Performance Panels
Well-characterized Chagas samples are essential to support development, evaluation, validation, and regulatory submissions for Chagas assays. SeraCare today introduced two new Chagas panels:

The Chagas (T. cruzi) AccuVert™ Seroconversion Panel, a 10-member panel of undiluted, naturally occurring plasma samples, is the first of its kind in the market. This rare and unique panel represents serial bleeds collected over the course of 118 days from a single individual during the development of a Chagas infection and subsequent response.

The Chagas (T. cruzi) Mixed Titer AccuSet™ Performance Panel is a 21-member panel of undiluted, naturally occurring plasma samples. Panel members represent bleeds from multiple individuals positive for Chagas disease from varying countries of origin.

Dengue Early Infection Performance Panel
The new Dengue Early Infection AccuSet™ Performance Panel is a 6-member panel of undiluted, naturally occurring plasma samples. Panel members represent serial bleeds collected over the course of 14 days from a single individual during the development of a Dengue infection and subsequent response. Test results from commercially-available Dengue assays are included for characterization of the panel members. This panel of human plasma samples is positive for Dengue RNA, NS1 antigen, and IgM and IgG antibodies.

SeraCare's new panels are available immediately worldwide. For more information, contact SeraCare Customer Service at +1 508-244-6400 / 1-800-676-1881 or visit www.seracare.com.

About SeraCare Life Sciences, Inc.
SeraCare partners with diagnostics researchers, IVD manufacturers, and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, KPL antibodies and immunoassay reagents, SeraCon processed plasma, specialty human blood products, and characterized disease state materials. SeraCare helps bridge the gap between today's diagnostic solutions and tomorrow's emerging technologies. For more information, visit www.seracare.com.

Company Contact:

Marsha Ann Marsh

Agency Contact:

Shannon Meirzon

SeraCare Life Sciences, Inc.

Pyxis Communications

508.244.6400 ext. 6106

203.550.5978/978.284.3254

mmarsh@seracare.com  

shannon@pyxiscommunications.com

www.seracare.com

www.pyxiscommunications.com

 

Photo - http://photos.prnewswire.com/prnh/20140625/121455

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WDRB. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.